

COMPETITIVE PROBLEMS IN THE DRUG INDUSTRY
(Present Status of Competition in the Pharmaceutical Industry)

WEDNESDAY, MAY 10, 1972

U.S. SENATE,
SUBCOMMITTEE ON MONOPOLY OF THE
SELECT COMMITTEE ON SMALL BUSINESS,
Washington, D.C.

The subcommittee met, pursuant to recess, at 10:00 a.m., in room 318, Old Senate Office Building, Senator Gaylord Nelson (chairman of the subcommittee) presiding.

Present: Senator Nelson.

Also present: Benjamin Gordon, staff economist; and Elaine C. Dye, clerical assistant.

Senator NELSON. Our witness this morning is Mr. Elmer Staats, Comptroller General of the United States.

Mr. Staats, the committee is pleased to have you here this morning. Your statement will be printed in full in the record.¹ You may present it however you desire.

Go ahead, Mr. Staats.

STATEMENT OF HON. ELMER B. STAATS, COMPTROLLER GENERAL OF THE UNITED STATES; ACCOMPANIED BY GREGORY J. AHART, DIRECTOR, MANPOWER AND WELFARE DIVISION; DEAN K. CROWTHER, DEPUTY DIRECTOR; CHARLES COLLINS, ASSISTANT DIRECTOR; AND PAUL SHNITZER, ASSISTANT GENERAL COUNSEL

Mr. STAATS. I will introduce my colleagues here, Mr. Chairman. I believe you are acquainted with most if not all of them.

To my immediate left is Mr. Gregory Ahart, Director of our Manpower and Welfare Division, a new division which we have just recently established, which is going to be concerned with all aspects of health programs throughout the Government.

Dean Crowther, to my right, is Deputy Director of that Division.

Mr. Collins, to his right, is Assistant Director of that Division.

Mr. Paul Shnitzer, to my far left here, is Assistant General Counsel of the GAO and has followed this area for quite some time.

Mr. Chairman, I have a fairly long statement, but we are dealing here in our statement with some seven different topics, so that I do not

¹ See Appendix II, p. 8801.